TrialVirology journal2025

Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.

Jiangtao Bai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.